Peptide / GLP-1

Semaglutide (Ozempic / Wegovy)

Once-weekly GLP-1 receptor agonist for fat loss and type 2 diabetes. Reduces appetite centrally, slows gastric emptying, improves insulin sensitivity. FDA-approved. Gold-standard GLP-1 therapy. Significant cardiovascular benefit demonstrated in SUSTAIN and STEP trials.

Build protocol outline Open dose calculator TNHL ebooks

Educational reference only. This page does not diagnose, prescribe, or replace care from a licensed professional. Laws, availability, and clinical appropriateness vary by location.

Reference dose0.25mg SubQ weekly x4 weeks → 0.5mg → 1mg → 2mg. Titrate slowly to minimize GI side effects.

Half-life168 hours

Risk flaglow

Regulatory noteFDA-approved context noted

Side effects and watch-outs

Nausea (very common — resolves with titration)
Vomiting
Diarrhea
Constipation
Decreased appetite
Injection site reaction
Rare: pancreatitis
Rare: thyroid C-cell tumors (animal data — monitor)
Muscle loss at high doses without resistance training